Dementia with Lewy bodies

Journal of the American Geriatrics Society

Volumn 46, Issue 11, 1998, Pages 1449-1458

  Gómez Tortosa, Estrella ^a   Ingraham, Aubrey O ^a   Irizarry, Michael C ^a   Hyman, Bradley T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; AUTOSOMAL DOMINANT INHERITANCE; DEMENTIA; DISEASE ASSOCIATION; GENETIC SUSCEPTIBILITY; HUMAN; LEWY BODY; NEUROFIBRILLARY TANGLE; REVIEW;

EID: 0031729004     PISSN: 00028614     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1532-5415.1998.tb06016.x     Document Type: Review

References (154)

1. Okazaki H, Lipton L, Aronson S. Diffuse intracytoplasmic ganglionic inclusions (Lewy type) associated with progressive dementia and quadriparesis in flexion. J Neurol Neurosurg Psychiatry 1961;20:237-244.
2. Hughes AJ. Clinicopathological aspects of Parkinson's disease. Eur Neurol 1997;38(suppl 2):13-20.
3. Kosaka K, Matsushita M, Oyanagi S et al. A clinicopathological study of "Lewy body disease." Psychiatr Neurol Jpn 1980;82:292-311.
4. Perry R, Jaros E, Irving D et al. What is the neuropathological basis of dementia associated with Lewy bodies? In: Perry R, McKeith I, Perry E, eds. Dementia with Lewy Bodies: Clinical, Pathological and Treatment Issues. Cambridge, UK: Cambridge University Press, 1996, pp 212-223.
5. Joachim C, Morris J, Selkoe D. Clinically diagnosed Alzheimer's disease: Autopsy results in 150 cases. Ann Neurol 1988;24:50-56.
6. Byrne E, Lennox G, Lowe J, Godwin-Austen R. Diffuse Lewy body disease: Clinical features in 15 cases. J Neurol Neurosurg Psychiatry 1989;52:709-717.
7. Perry R, Irving D, Blessed G et al. Senile dementia of Lewy body type: A clinically and neuropathologically distinct form of Lewy body dementia in the elderly. J Neurol Sci 1990;95:119-139.
8. Hansen L, Salmon D, Galasko D et al. The Lewy body variant of Alzheimer's disease: A clinical and pathological entity. Neurology 1990;40:1-8.
9. Hansen L, Masliah E, Galasko D, Terry R. Plaque-only Alzheimer disease is usually the Lewy body variant, and vice versa. J Neuropathol Exp Neurol 1993;52:648-654.
10. Galasko D, Hansen L, Katzman R et al. Clinical-neuropathological correlations in Alzheimer's disease and related dementias. Arch Neurol 1994;51: 888-895.
11. Kosaka K. Dementia and neuropathology in Lewy body disease. Adv Neurol 1993;60:456-463.
12. Burns A. Clinical features of patients with Alzheimer's disease and Lewy bodies. In: Perry R, McKeith I, Perry E, eds. Dementia with Lewy Bodies: Clinical, Pathological and Treatment Issues. Cambridge, UK: Cambridge University Press, 1996, pp 46-56.
13. Olichney J, Hofstetter C, Salmon D et al. Cognitive decline is faster in Lewy body variant than in Alzheimer's disease. Neurology (Abstract) 1997; 48:140.
14. Salmon DP, Galasko D, Hansen LA et al. Neuropsychological deficits associated with diffuse Lewy body disease. Brain Cogn 1996;31:148-165.
15. Gibb W, Esiri M, Lees A. Clinical and pathological features of diffuse cortical Lewy body disease (Lewy body dementia). Brain 1987;110:1131-1153.
16. Galasko D, Katzman R, Salmon DP, Hansen L. Clinical and neuropathological findings in Lewy body dementias. Brain Cogn 1996;31:166-175.
17. Louis ED, Klatka LA, Liu Y, Fahn S. Comparison of extrapyramidal features in 31 pathologically confirmed cases of diffuse Lewy body disease and 34 pathologically confirmed cases of Parkinson's disease. Neurology 1997; 48:376-380.
18. Ballard C, Lowery K, Harrison R, McKeith I. Noncognitive symptoms in Lewy body dementia. In: Perry R, McKeith I, Perry E, eds. Dementia with Lewy Bodies: Clinical, Pathological and Treatment Issues. Cambridge, UK: Cambridge University Press, 1996, pp 67-84.
19. McShane R, Keene J, Gedling K, Hope T. Hallucinations, cortical Lewy body pathology, cognitive function and neuroleptic use in dementia. In: Perry R, McKeith I, Perry E, eds. Dementia with Lewy Bodies: Clinical, Pathological and Treatment Issues. Cambridge, UK: Cambridge University Press, 1996, pp 85-98.
20. Klatka LA, Louis ED, Schiffer RB. Psychiatric features in diffuse Lewy body disease: A clinicopathologic study using Alzheimer's disease and Parkinson's disease comparison groups. Neurology 1996;47:1148-1152.
21. Kosaka K. Diffuse Lewy body disease in Japan. J Neurol 1990;237:197-204.
22. McKeith I, Galasko D, Kosaka K et al. Consensus guidelines for the clinical and pathological diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology 1996;47:1113-1124.
23. Byrne E, Lennox G, Godwin-Austen R et al. Diagnostic criteria for dementia associated with cortical Lewy bodies. Dementia 1991;2:283-284.
24. McKeith I, Perry R, Fairbairn A et al. Operational criteria for senile dementia of Lewy body type (SDLT). Psychol Med 1992;22:911-922.
25. Burkhardt C, Filley C, Kleinschmidt-DeMasters B et al. Diffuse Lewy body disease and progressive dementia. Neurology 1988;38:1520-1528.
26. Yamamoto T, Imai T. A case of diffuse Lewy body and Alzheimer's disease with periodic synchronous discharges. J Neuropathol Exp Neurol 1988;47: 536-548.
27. Crystal H, Dickson D, Lizardi J et al. Antemortem diagnosis of diffuse Lewy body disease. Neurology 1990;40:1523-1528.
28. Albin R, Minoshima S, D'Amato C et al. Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease. Neurology 1996;47: 462-466.
29. Ishii K, Imamura T, Sasaki M et al. Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease. Neurology 1998; 51:125-130.
30. Donnemiller E, Heilmann J, Wenning GK et al. Brain perfusion scintigraphy with 99mTc-HMPAO or 99mTc-ECD and 123I-beta-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease. Eur J Nucl Med 1997;24:320-325.
31. Walker Z, Costa D, Janssen A et al. Dementia with Lewy bodies: A study of post-synaptic dopaminergic receptors with iodine-123 iodobenzamide single-photon emission tomography. Eur J Nucl Med 1997;24:609-614.
32. Spellman G. Report of familial cases of parkinsonism. JAMA 1962;179: 372-374.
33. Muenter M, Howard FJ, Okazaki H et al. A familial parkinson-dementia syndrome. Neurology (Suppl 1) 1986;36:115.
34. Inose T, Miyakawa M, Miyakawa K et al. Clinical and neuropathological study of a familial case of juvenile parkinsonism. Jpn J Psychiatry Neurol 1989;42:265-276.
35. Golbe L, Lazarini A, Schwartz K et al. Autosomal dominant parkinsonism with benign course and typical Lewy-body pathology. Neurology 1993;43: 2222-2227.
36. Waters C, Miller C. Autosomal dominant Lewy body parkinsonism in a four-generation family. Ann Neurol 1994;35:59-64.
37. Denson MA, Wszolek ZK, Pfeiffer RF et al. Familial parkinsonism, dementia, and Lewy body disease: Study of family G. Ann Neurol 1997;42:638-643.
38. Ishikawa A, Takahashi H, Tanaka H et al. Clinical features of familial diffuse Lewy body disease. Eur Neurol 1997;38(suppl 1):34-38.
39. Marder K, Flood P, Cote L, Mayeux R. A pilot study of risk factors for dementia in Parkinson's disease. Mov Disord 1990;5:156-161.
40. Hofman A, Schulte W, Tanja T et al. History of dementia and Parkinson's disease in 1st-degree relative of patients with Alzheimer's disease. Neurology 1989;39:1589-1592.
41. Majoor-Krakauer D, Ottman R, Johnson W, Rowland L. Familial aggregation of amyotrophic lateral sclerosis, dementia, and Parkinson's disease: Evidence of shared genetic susceptibility. Neurology 1994;44:1872-1877.
42. Iwai A, Masliah E, Yoshimoto M et al. The precursor protein of non-Aβ component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 1995;14:467-475.
43. Polymeropoulos MH, Lavedan C, Leroy E et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276:2045-2047.
44. Munoz E, Oliva R, Obach V et al. Identification of Spanish familial Parkinson's disease and screening for the Ala53Thr mutation of the alpha-synuclein gene in early onset patients. Neurosci Lett 1997;235:57-60.
45. The French Parkinson's Disease Genetics Study Group. Alpha-synuclein gene and Parkinson's disease. Science 1998;279:1116-1117.
46. Chan P, Tanner CM, Jiang X, Langston JW. Failure to find the alpha-synuclein gene missense mutation (G209A) in 100 patients with younger onset Parkinson's disease. Neurology 1998;50:513-514.
47. Farrer M, Wavrant-De Vrieze F, Crook R et al. Low frequency of alpha-synuclein mutations in familial Parkinson's disease. Ann Neurol 1998;43: 394-397.
48. Kruger R, Kuhn W, Muller T et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998;18:106-108.
49. Spillantini M, Schmidt M, Lee V et al. Alpha-synuclein in Lewy bodies. Nature 1997;388:839-840.
50. Irizarry M, Growdon W, Gomez-Isla T et al. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity. J Neuropathol Exp Neurol 1998;57:334-337.
51. Takeda A, Mallory M, Sundsmo M et al. Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders. Am J Pathol 1998; 152:367-372.
52. Irizarry M, Kim T, McNamara M et al. Characterization of the precursor protein of the non-Aβ component of senile plaques (NACP) in the human central nervous system. J Neuropathol Exp Neurol 1996;55:889-895.
53. Masliah E, Iwai A, Mallory M et al. Altered presynaptic protein NACP is associated with plaque formation and neurodegeneration in Parkinson's disease. Am J Pathol 1996;148:201-210.
54. Armstrong M, Daly A, Cholerton S et al. Mutant debrisoquine hydroxylation genes in Parkinson's disease. Lancet 1992;339:1017-1018.
55. Smith C, Gough A, Leigh P et al. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet 1992;339:1375-1377.
56. Kurth M, Kurth J. Variant cytochrome P450 CYP2D6 allelic frequencies in Parkinson's disease. Am J Med Genet 1993;48:166-168.
57. McCann SJ, Pond SM, James KM, Le Couteur DG. The association between polymorphisms in the cytochrome P-450 2D6 gene and Parkinson's disease: A case-control study and meta-analysis. J Neurol Sci 1997;153:50-53.
58. Agundez JA, Jimenez-Jimenez FJ, Luengo A et al. Association between the oxidative polymorphism and early onset of Parkinson's disease. Clin Pharmacol Ther 1995;57:291-298.
59. Saitoh T, Xia Y, Chen X et al. The CYP2D6B mutant allele is overrepresented in the Lewy body variant of Alzheimer's disease. Ann Neurol 1995; 37:110-112.
60. Plante-Bordeneuve V, Davis M, Maraganore D et al. Debrisoquine hydroxylase gene polymorphism in familial Parkinson's disease. J Neurol Neurosurg Psychiatry 1994;57:911-913.
61. Gasser T, Muller-Myhsok B, Supala A et al. The CYP2D6B allele is not overrepresented in a population of German patients with idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1996;61:518-520.
62. Diederich N, Hilger C, Goetz CG et al. Genetic variability of the CYP 2D6 gene is not a risk factor for sporadic Parkinson's disease. Ann Neurol 1996; 40:463-465.
63. Sandy MS, Armstrong M, Tanner CM et al. CYP2D6 allelic frequencies in young-onset Parkinson's disease. Neurology 1996;47:225-230.
64. Tsuneoka Y, Matsuo Y, Ichikawa Y, Watanabe Y. Genetic analysis of the CYP2D6 gene in patients with Parkinson's disease. Metabolism 1998;47: 94-96.
65. Saitoh T, Katzman R. Genetic correlations in Lewy body disease. In: Perry R, McKeith I, Perry E, eds. Dementia with Lewy Bodies: Clinical, Pathological and Treatment Issues. Cambridge, UK: Cambridge University Press, 1996, pp 336-349.
66. Gasser T, Muller-Myhsok B, Wszolek Z et al. A susceptibility locus for Parkinson's disease maps to chromosome 2p13. Nat Genet 1998;18:262-265.
67. Kitada T, Asakawa S, Hattori N et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998;329:605-608.
68. Saunders A, Strittmatter W, Schmechel D et al. Association of apolipoprotein E allele epsilon4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993;43:1467-1472.
69. Rebeck WG, Reiter JS, Strickland DK, Hyman B Apolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interactions. Neuron 1993;11:575-580.
70. Pickering-Brown S, Mann D, Bourke J et al. Apolipoprotein E4 and Alzheimer's disease pathology in Lewy body disease and in other β-amyloid-forming diseases. Lancet (Letter)1994;343:1155.
71. Benjamin R, Leake A, Ince PG et al. Effects of apolipoprotein E genotype on cortical neuropathology in senile dementia of the Lewy body and Alzheimer's disease. Neurodegeneration 1995;4:443-448.
72. Hansen L, Galasko D, Samuel W et al. Apolipoprotem-E epsilon-4 is associated with increased neurofibrillary pathology in the Lewy body variant of Alzheimer's disease. Neurosci Lett 1994;182:63-65.
73. Harrington C, Louwagie J, Rossau R et al. Influence of the apolipoprotein E genotype on senile dementia of the Alzheimer and Lewy body types: Significance for etiological theories of Alzheimer's disease. Am J Pathol 1994; 145:1472-1482.
74. Lippa CF, Smith TW, Saunders AM et al. Apolipoprotein E genotype and Lewy body disease. Neurology 1995;45:97-103.
75. Galasko D, Saitoh Y, Xia Y et al. The apolipoprotein E allele epsilon 4 is over represented in patients with the Lewy body variant of Alzheimer's disease. Neurology 1994;44:1950-1951.
76. Dickson DW, Crystal H, Davies P, Hardy J. Cytoskeletal and Alzheimer-type pathology in Lewy body disease. In: Perry R, McKeith I, Perry E, eds. Dementia with Lewy Bodies: Clinical, Pathological and Treatment Issues. Cambridge, UK: Cambridge University Press, 1996, pp 224-237.
77. Koller WC, Glatt SL, Hubble JP et al. Apolipoprotein E genotypes in Parkinson's disease with and without dementia. Ann Neurol 1995;37:242-245.
78. Kurth J, Kurth M, Poduslo S, Schwankhaus J. Association of a monoamine oxidase B allele with Parkinson's disease. Ann Neurol 1993;33:368-372.
79. Hotamisligil G, Girmen A, Fink J et al. Hereditary variations in monoamine oxidase as a risk factor for Parkinson's disease. Mov Disord 1994;9: 305-310.
80. Ho SL, Kapadi AL, Ramsden DB, Williams AC. An allelic association study of monoamine oxidase B in Parkinson's disease. Ann Neurol 1995;37:403-405.
81. Plante-Bordeneuve V, Taussig D, Thomas F et al. Evaluation of four candidate genes encoding proteins of the dopamine pathway in familial and sporadic Parkinson's disease: evidence for association of a DRD2 allele. Neurology 1997;48:1589-1593.
82. Hoda F, Nicholl D, Bennett P et al. No association between Parkinson's disease and low-activity alleles of catechol O-methyltransferase. Biochem Biophys Res Commun 1996;228:780-784.
83. Syvanen AC, Tilgmann C, Rinne J, Ulmanen I. Genetic polymorphism of catechol-O-methyltransferase (COMT): Correlation of genotype with individual variation of S-COMT activity and comparison of the allele frequencies in the normal population and parkinsonian patients in Finland. Pharmacogenetics 1997;7:65-71.
84. Xie T, Ho SL, Li LS, Ma OC. G/A1947 polymorphism in catechol-O-methyltransferase (COMT) gene in Parkinson's disease. Mov Disord 1997; 12:426-427.
85. Kunugi H, Nanko S, Ueki A et al. High and low activity alleles of catechol-O-methyltransferase gene: Ethnic difference and possible association with Parkinson's disease. Neurosci Lett 1997;221:202-204.
86. Plante-Bordeneuve V, Davis M, Maraganore D et al. Tyrosine hydroxylase gene polymorphism in familial and sporadic Parkinson's disease. Mov Disord 1994;9:337-339.
87. Ludecke B, Knappskog PM, Clayton PT et al. Recessively inherited L-DOPA-responsive parkinsonism in infancy caused by a point mutation (L205P) in the tyrosine hydroxylase gene. Hum Mol Genet 1996;5:1023-1028.
88. Higuchi S, Muramatsu T, Arai H et al. Polymorphisms of dopamine receptor and transporter genes and Parkinson's disease. J Neural Transm 1995; 10:107-113.
89. Kobayashi T, Matsumine H, Matuda S, Mizuno Y. Association between the gene encoding the E2 subunit of the alpha-ketoglutarate dehydrogenase complex and Parkinson's disease. Ann Neurol 1998;43:120-123.
90. Kosaka K, Iseki E. Dementia with Lewy bodies. Curr Opin Neurol 1996;9: 271-275.
91. Mezey E, Dehejia A, Harta G et al. Alpha synuclein in neurodegenerative disorders: murderer or accomplice? Nat Med 1998;4:755-757.
92. Dale G, Probst A, Luthert P et al. Relationships between Lewy bodies and pale bodies in Parkinson's disease. Acta Neuropathol (Berl) 1992;83:525-529.
93. Rezaie P, Cairns NJ, Chadwick A, Lantos PL. Lewy bodies are located preferentially in limbic areas in diffuse Lewy body disease. Neurosci Lett 1996; 212:111-114.
94. Iseki E, Odawara T, Kosaka et al. A quantitative study of Lewy bodies and senile changes in the amygdala in diffuse Lewy body disease. Neuropathol Appl Neurobiol 1995;15:112-116.
95. Wakabayashi K, Hansen LA, Masliah E. Cortical Lewy body-containing neurons are pyramidal cells: Laser confocal imaging of double-immunolabeled sections with anti-ubiquitin and SMI32. Acta Neuropathol (Berl) 1995;89:404-408.
96. Goldman J, Yna S, Chiu F, Peress N. Lewy bodies of Parkinson's disease contain neurofilament antigens. Science 1983;221:1082-1084.
97. Forno L, Sternberger L, Sternberger N et al. Reaction of Lewy bodies with antibodies to phosphorylated and non-phosphorylated neurofilaments. Neurosci Lett 1986;64:253-258.
98. Galloway P, Grundke-Iqbal I, Iqbal K, Perry G. Lewy bodies contain epitopes both shared and distinct from Alzheimer's neurofibrillary tangles. J Neuropathol Exp Neurol 1988;47:654-663.
99. Galloway P, Mulvihill P, Perry G. Filaments of Lewy bodies contain insoluble cytoskeletal elements. Am J Pathol 1992;140:809-822.
100. Bancher C, Lassmann H, Budka H et al. An antigenic profile of Lewy bodies: Immunocytochemical indication for protein phosphorylation and ubiquitination. J Neuropathol Exp Neurol 1989;48:81-93.
101. Schmidt M, Murray J, Lee V-Y et al. Epitope map of neurofilament protein domains in cortical and peripheral nervous system Lewy bodies. Am J Pathol 1991;139:53-65.
102. Hill W, Lee V-Y, Hurtig H et al. Epitopes located in spatially separate domains of each neurofilament subunit are present in Parkinson's disease Lewy bodies. J Comp Neurol 1991;309:150-160.
103. Pollanen M, Bergeron C, Weyer L. Detergent-insoluble cortical Lewy body fibrils share epitopes with neurofilament and tau. J Neurochem 1992;58: 1953-1956.
104. Smith MC, Mallory M, Hansen LA et al. Fragmentation of the neuronal cytoskeleton in the Lewy body variant of Alzheimer's disease. Neuroreport 1995;6:673-676.
105. Galvin JE, Lee VM, Baba M et al. Monoclonal antibodies to purified cortical Lewy bodies recognize the mid-size neurofilament subunit. Ann Neurol 1997;42:595-603.
106. Kuzuhara S, Mori H, Izumiyama N et al. Lewy bodies are ubiquitinated: A light and electron microscopic immunocytochemical study. Acta Neuropathol (Berl) 1988;75:345-353.
107. Gai WP, Blumbergs PC, Blessing WW. Microtubule-associated protein 5 is a component of Lewy bodies and Lewy neurites in the brainstem and forebrain regions affected in Parkinson's disease. Acta Neuropathol (Berl) 1996;91:78-81.
108. Arai H, Lee V-Y, Hill W et al. Lewy bodies contain beta-amyloid precursor proteins of Alzheimer's disease. Brain Res 1992;585:386-390.
109. Trojanowski JQ, Lee VM. Aggregation of neurofilament and alpha-synuclein proteins in Lewy bodies: Implications for the pathogenesis of Parkinson disease and Lewy body dementia. Arch Neurol 1998;55:151-152.
110. Iwatsubo T, Nakano I, Fukunaga K, Miyamoto E. Ca2+/calmodulin-dependent protein kinase II immunoreactivity in Lewy bodies. Acta Neuropathol (Berl) 1991;82:159-163.
111. Brion JP, Couck AM. Cortical and brainstem-type Lewy bodies are immunoreactive for the cyclin-dependent kinase 5. Am J Pathol 1995;147:1465-1476.
112. Nishimura M, Tomimoto H, Suenaga T et al. Synaptophysin and chromogranin A immunoreactivities of Lewy bodies in Parkinson's disease brains. Brain Res 1994;634:339-344.
113. Lowe J, Blanchard A, Morrell K et al. Ubiquitin is a common factor in intermediate filament inclusion bodies of diverse type in man, including those of Parkinson's disease, Pick's disease, and Alzheimer's disease as well as Rosenthal fibres in cerebellar astrocytomas, cytoplasmic bodies in muscle and Mallory's bodies in alcoholic liver disease. J Pathol 1988;155:9-15.
114. Manetto V, Perry G, Tabaton M et al. Ubiquitin is associated with abnormal cytoplasmic filaments characteristic of neurodegenerative disease. Proc Natl Acad Sci U S A 1988;85:4501-4505.
115. Lennox G, Lowe J, Morrell K et al. Antiubiquitin immunocytochemistry is more sensitive than conventional techniques in the detection of diffuse Lewy body disease. J Neurol Neurosurg Psychiatry 1989;52:67-71.
116. Love S, Nicoll A. Comparison of modified Bielschowsky silver impregnation and anti-ubiquitin immunostainig of cortical and nigral Lewy bodies. Neuropathol Appl Neurobiol 1992;18:585-592.
117. Lowe J, McDermott H, Landon M et al. Ubiquitin carboxy-terminal hydrolase (PGP9.5) is selectively present in ubiquitinated inclusion bodies characteristic of human neurodegenerative disease. J Pathol 1990;161:153-160.
118. Lowe J, Landon M, Pike I et al. Dementia with β-amyloid deposition: Involvement of αB-crystallin supports two main diseases. Lancet 1990;336: 515-516.
119. Lowe J, McDermott H, Pike I et al. αB crystallin expression in non-lenticular tissues and selective presence in ubiquitinated inclusion bodies in human disease. J Pathol 1992;166:61-68.
120. Kwak S, Masaki T, Ishiura S, Sugita H. Multicatalytic proteinase is present in Lewy bodies and neurofibrillary tangles in diffuse Lewy body disease brains. Neurosci Lett 1991;128:21-24.
121. Ito H, Ii K, Hirano A, Dickson D. Immunohistochemical identification of the proteasome in ubiquitin reactive abnormal structures of the nervous system. J Neuropathol Exp Neurol (Abstract)1991;50:360.
122. Yamada T, McGeer P, McGeer E. Lewy bodies in Parkinson's disease are recognized by antibodies to complement proteins. Acta Neuropathol (Berl) 1992;84:100-104.
123. Papolla M, Adorn A, Chou S. Serum protein antigens with Lewy bodies of Parkinson's disease. Ann Neurol (abstract) 1984;66:136.
124. Nishiyama K, Murayama S, Shimizu J et al. Cu/Zn superoxide dismutase-like immunoreactivity is present in Lewy bodies from Parkinson's disease: A light and electron microscopic immunocytochemical study. Acta Neuropathol (Berl) 1995;89:471-474.
125. Yamada T, McGeer P, Baimbridge K, McGeer E. Relative sparing in Parkinson's disease of substantia nigra dopamine neurons containing calbindin-D28 k. Brain Res 1990;526:303-307.
126. Pollanen M, Dickson D, Bergeron C. Pathology and biology of the Lewy body. J Neuropathol Exp Neurol 1993;52:183-191.
127. Lowe J. Lewy bodies. In: Neurodegenerative Diseases. Philadelphia: WB Saunders, 1994.
128. Lowe J, Mayer R, Landon M. Pathological significance of Lewy bodies in dementia. In: Perry R, McKeith I, Perry E, eds. Dementia with Lewy Bodies: Clinical, Pathological and Treatment Issues. Cambridge, UK: Cambridge University Press, 1996, pp 195-203.
129. Bergeron C, Petrunka C, Weyer L, Pollanen MS. Altered neurofilament expression does not contribute to Lewy body formation. Am J Pathol 1996; 148:267-272.
130. Dickson D, Ruan D, Crystal H et al. Hippocampal degeneration differentiates diffuse Lewy body disease (DLBD) from Alzheimer's disease: Light and electron microscopic immunocytochemistry of CA2-3 neurites specific to DLBD. Neurology 1991;41:1402-1409.
131. Braak H, Braak E, Yilmazer D et al. Amygdala pathology in Parkinson's disease. Acta Neuropathol (Berl) 1994;88:493-500.
132. Dickson D, Schmidt M, Lee V-Y et al. Hippocampal neurites in diffuse Lewy body disease: Immunocytochemical characterization and local origin. Acta Neuropathol (Berl) 1994;87:269-276.
133. Hansen L. Tautological tangles in neuropathological criteria for dementias associated with Lewy bodies. In: Perry R, McKeith I, Perry E, eds. Dementia with Lewy Bodies: Clinical, Pathological and Treatment Issues. Cambridge, UK: Cambridge University Press, 1996, pp 204-211.
134. Gibb W, Mountjoy C, Mann D, Lees A. A pathological study of the association between Lewy body disease and Alzheimer's disease. J Neurol Neurosurg Psychiatry 1989;52:701-708.
135. Strong C, Anderton BH, Perry RH et al. Abnormally phosphorylated tau protein in senile dementia of Lewy body type and Alzheimer disease: Evidence that the disorders are distinct. Alzheimer Dis Assoc Disord 1995;9: 218-222.
136. Samuel W, Crowder R, Hofstetter CR, Hansen L. Neuritic plaques in the Lewy body variant of Alzheimer disease lack paired helical filaments. Neurosci Lett 1997;223:73-76.
137. Masliah E, Mallory M, Hansen L et al. Quantitative synaptic alterations in the human neocortex during normal aging. Neurology 1993;43:192-197.
138. Crystal H, Dickson D, Sliwinski M et al. Pathological markers associated with normal aging and dementia in the elderly. Ann Neurol 1993;34:566-573.
139. Dickson D, Crystal H, Mattiace L et al. Identification of normal and pathological aging in prospectively studied nondemented elderly humans. Neurobiol Aging 1992;13:179-189.
140. Gomez-Isla T, West H, Rebeck G et al. Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer's disease. Ann Neurol 1996;39: 62-70.
141. Dickson D, Crystal H, Mattiace L et al. Diffuse Lewy body disease: Light and electron microscopic immunocytochemistry of senile plaques. Acta Neuropathol (Berl) 1989;78:572-584.
142. Dickson D, Wu E, Crystal H et al. Alzheimer and age-related changes in diffuse Lewy body disease. In: Boller FF, Kachaturian Z, Poncet M, Christen Y, eds. Heterogeneity of Alzheimer's Disease. Berlin: Springer-Verlag, 1992, pp 168-186.
143. Armstrong R, Cairns N, Lantos P. β-Amyloid (Aβ) deposition in the medial temporal lobe of patients with dementia with Lewy bodies. Neurosci Lett 1997;227:193-196.
144. Masliah E, Mallory M, DeTeresa R et al. Differing patterns of aberrant neuronal sprouting in Alzheimer's disease with and without Lewy bodies. Brain Res 1993;617:258-266.
145. Samuel W, Alford M, Hofstetter CR, Hansen L. Dementia with Lewy bodies versus pure Alzheimer disease: Differences in cognition, neuropathology, cholinergic dysfunction, and synapse density. J Neuropathol Exp Neurol 1997;56:499-508.
146. Lippa CF, Pulaski-Salo D, Dickson DW, Smith TW. Alzheimer's disease, Lewy body disease and aging: A comparative study of the perforant pathway. J Neurol Sci 1997;147:161-166.
147. Iseki E, Li F, Kosaka K. Close relationship between spongiform change and ubiquitin-positive granular structures in diffuse Lewy body disease. J Neurol Sci 1997;146:53-57.
148. Hansen L, Masliah E, Terry R et al. A neuropathological subset of Alzheimer's disease with concomitant Lewy body disease and spongiform change. Acta Neuropathol (Berl) 1989;78:194-201.
149. Sima A, Clark A, Stemberger N, Stemberger L. Lewy body dementia without Alzheimer changes. Can J Neurol Sci 1986;13:490-497.
150. Kuljis R, Martin-Vasallo P, Peress N. Lewy bodies in tyrosine hydroxylase synthesizing neurons of the human cerebral cortex. Neurosci Lett 1989; 106:49-54.
151. Perry E, Marshall E, Perry R et al. Cholinergic and dopaminergic activities in senile dementia of the Lewy body type. Alzheimer Dis Assoc Disord 1990;4:87-95.
152. Liu Y, Stern Y, Chun M et al. Pathological correlates of extrapyramidal signs in Alzheimer's disease. Ann Neurol 1997;41:368-374.
153. Lennox G, Lowe J, Landon M et al. Diffuse Lewy body disease, correlative neuropathology using anti-ubiquitin immunocytochemistry. J Neurol Neurosurg Psychiatry 1989;52:1236-1247.
154. Samuel W, Galasko D, Masliah E, Hansen LA. Neocortical lewy body counts correlate with dementia in the Lewy body variant of Alzheimer's disease. J Neuropathol Exp Neurol 1996;55:44-52.